US drug firms say $26bn opioid settlement will proceed

Distributors say 42 states, five territories and Washington have signed on to deal resolving claims they fuelled opioid epidemic

Mediclinic inks R2.2bn deal aimed at ramping up local renewable energy supply

The group aims at procurement from independent power producers to be carbon neutral by 2030

Discovery first on JSE to introduce mandatory jabs for all staff

It’s a moral imperative, says CEO Adrian Gore, after the company lost 14,000 clients to Covid-19

Aspen looks to expand vaccine production in SA beyond Covid-19

Aspen has capacity to produce 1.35-billion vaccine doses at its Gqeberha facility and is now using less than a quarter of that to help make J&J’s Covid-19 shot

Aspen slashes debt and reinstates dividends

Pharmaceutical’s maker net debt falls by more than half

J&J halts HIV vaccine trial in Southern Africa

The trial, called Imbokodo, shows the vaccine is just 25% effective against preventing infection over two years ​​

PODCAST | Cybersecurity threats to posting Covid-19 vaccination cards online

Mudiwa Gavaza is joined by Duane Nicol, cybersecurity expert at Mimecast

Vaccine booster after six months provides stronger protection, says J&J

People who receive Johnson & Johnson’s one-shot Covid-19 jab could benefit from a follow-up shot later in 2021

Dis-Chem founder’s share sale nets R1.96bn

The pharmacy group says it enjoyed strong demand in a share sale as the founding Saltzman family hands over to new management

Adcock Ingram eyes broad-based growth after striking product balance

Drug maker has been pushing into products that are not price regulated, which now contribute half of its revenue

AstraZeneca's new Covid-19 antibody therapy gives hope to people who are immunocompromised

British drugmaker's new antibody therapy reduced the risk of people developing any Covid-19 symptoms by 77% in a late-stage trial

WATCH: Vaccine rollout offers strategy for future collaboration

Michael Avery and guests take a look at the progress made in the country’s Covid-19 vaccination rollout

Sanofi raises profit outlook after strong second quarter

French drugmaker posts nearly  €9bn in revenue for the quarter

Covid-19 vaccine set to be one of Pfizer’s all-time best sellers

The US drugmaker had previously projected vaccine sales for the year of $26bn

Hot stock Moderna joins S&P as most heavily traded company in 2021

But parallels with Tesla don’t necessarily bode well for the stock amid a debut dip

Ascendis inks R770m deal to sell its animal-health division

Debt-ravaged group is selling off businesses to avoid business rescue.

Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.